Clinical Trials Browser

Recurrence × Alpelisib × Gynecologic × Clear all

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence